Skip to main content
Clinical Trials/NCT01540955
NCT01540955CompletedPhase 2

Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors

Jonsson Comprehensive Cancer Center1 site in 1 country48 target enrollmentStarted: April 1, 2012Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
48
Locations
1
Primary Endpoint
Cognitive function measured by neuropsychological assessment 2 months after group intervention

Study Overview

Brief Summary

There are over 2 million breast cancer survivors in the US today. Along with extended survival, many women experience short and long-term after effects of treatment, which may decrease their quality of life and contribute to other health problems. Cognitive complaints---difficulties with memory, concentration, and planning-are commonly reported after adjuvant treatments for breast cancer. This study is designed to test the efficacy of a 5 week group-based cognitive rehabilitation intervention on improving cognitive complaints and test performance, in comparison to women who will receive the same intervention at a later time (wait-list control). Women will also have an EEG test performed before and after the intervention program to see if improvements in cognitive complaints and performance can be documented by examining the EEG.

Detailed Description

Previous pilot work (non-randomized, pre-post design) has shown that this intervention was effective in improving post-intervention cognitive complaints and neuropsychological (NP) test performance. Because practice effects may influence NP performance, it is important to compare the intervention participants to women who are not exposed to the intervention. Thus, this randomized controlled trial will compare the active intervention to a control group of patients who will receive the intervention at a delayed time point. The primary outcomes are improvements in cognitive complaints and NP test performance 2 months after completion of the intervention program. Quantitative EEG (QEEG) measurements will be used as a secondary exploratory endpoint to see if this may be an effective biomarker of cognitive performance.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
21 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •age 21-65 years
  • •stage I, II, III breast cancer diagnosis within the past 18 months to 5 years
  • •currently disease free, but may be on endocrine therapy
  • •with evidence of need of cognitive therapeutic intervention, as demonstrated by mild or greater cognitive deficiencies on an objective screening measure
  • •reads and writes English
  • •able to give informed consent
  • •willing and able to attend 5 weekly group sessions and participate in pre and post-evaluation that will take place on the UCLA campus

Exclusion Criteria

  • •evidence of uncontrolled depression

Arms & Interventions

Group Intervention program

Experimental

Intervention: Improving Cognition with group intervention (Behavioral)

Wait-list control group

No Intervention

The wait-list-control group will also be able to participate in the group intervention, but not until after all the study visits have been completed.

Outcomes

Primary Outcomes

Cognitive function measured by neuropsychological assessment 2 months after group intervention

Time Frame: 2 months

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials